Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTENSE: Perioperative FOLFOXIRI for Gastric and GE Junction Adenocarcinoma
NCT03773367Phase 2Active, not recruiting
- Sponsor
- Skåne University Hospital
- Start
- Dec 2018
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of irinotecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Skåne University Hospital. Started Dec 2018; status: active, not recruiting.
02
Drugs
irinotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03773367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773367.